Free Trial
OTCMKTS:CLPBY

Coloplast A/S 8/19/2025 Earnings Report

Coloplast A/S logo
$9.58 -0.02 (-0.22%)
As of 03:58 PM Eastern

Coloplast A/S EPS Results

Actual EPS
$0.06
Consensus EPS
$0.09
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Coloplast A/S Revenue Results

Actual Revenue
$1.09 billion
Expected Revenue
$7.10 billion
Beat/Miss
Missed by -$6.01 billion
YoY Revenue Growth
N/A

Coloplast A/S Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Coloplast A/S' next earnings date is estimated for Tuesday, November 4, 2025, based on past reporting schedules.

Conference Call Resources

Coloplast A/S Earnings Headlines

Coloplast A/S (CLPBF) Q3 2025 Earnings Call Transcript
Trump’s national nightmare is here
While the headlines focus on global conflicts, there’s a very different crisis brewing at home. Washington has quietly invoked emergency powers, issued executive orders, and begun funneling trillions into a rapid economic mobilization. This isn’t a war — not officially — but the scale of what’s coming could reshape markets and impact billions of lives. Most investors are completely unaware, yet the implications for your money are enormous.tc pixel
Coloplast A/S - Interim Financial Report, 9M 2024/25
Coloplast A/S (CLPBY) Projected to Post Earnings on Tuesday
See More Coloplast A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coloplast A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coloplast A/S and other key companies, straight to your email.

About Coloplast A/S

Coloplast A/S (OTCMKTS:CLPBY) engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

View Coloplast A/S Profile

More Earnings Resources from MarketBeat